Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Emma Gibbs"'
Autor:
Rona Bronwin, Ian Attfield, Charlotte Jones, Laura Savage, Jess Atkinson, Emma Gibbs, Amy Potter, Rachel Hinton
Publikováno v:
Compare: A Journal of Comparative and International Education. 51:137-156
A small research team has recently been scouring the global education landscape for examples of education projects that are working at scale to improve learning outcomes (Dubeck et al. 2019). They ...
Autor:
Frances M. Boyle, Robin John Paterson, Prudence A. Francis, Lauren Macnab, Anne Hamilton, Rebecca Asher, Edmond M. Kwan, Emma Gibbs, Chee Khoon Lee, Geoffrey J. Lindeman, Michael Friedlander, Elizabeth Lieschke, Heath Badger, Clare L. Scott
Publikováno v:
British Journal of Cancer
Background We conducted a Phase 1 study to evaluate safety and activity of olaparib tablets and oral cyclophosphamide. Methods Patients had metastatic breast cancer (BC) or recurrent high-grade serous ovarian cancer (HGSOC), performance status 0–2,
Autor:
Ralph Bloomfield, Jacob Korach, Michael Friedlander, Eric Pujade-Lauraine, Tomasz Huzarski, Daniel Eek, Clare L. Scott, Richard T. Penson, Lari Wenzel, Emma Gibbs, Diane Provencher, Florence Joly, Manuel Rodrigues, Felix Hilpert, Kenji Tamura, Val Gebski, Lucy Davies, Andrew R Clamp, David Espinoza, Vanda Salutari, Laura Vidal, Maria Ornella Nicoletto
Publikováno v:
The Lancet Oncology. 19:1126-1134
Summary Background In the phase 3 SOLO2 trial (ENGOT Ov-21), maintenance therapy with olaparib tablets significantly prolonged progression-free survival (primary endpoint) compared with placebo in patients with a germline BRCA1 or BRCA2 (BRCA1/2) mut
Autor:
Violet Mukaro, Mustafa Khasraw, Robert Tobler, Linda West, Sally Baron-Hay, Bruno Giuffre, Rebecca Asher, Caitlin Murphy, Emma Gibbs
Publikováno v:
Internal Medicine Journal. 48:699-705
BACKGROUND Magnetic resonance imaging (MRI) accuracy after neoadjuvant systemic therapy (NST) for breast cancer varies according to hormone receptor (HR), human epidermal growth factor receptor type-2 (HER2) subtype and Ki-67 proliferation index. Whe
Publikováno v:
Journal of Neonatology. 32:15-21
Objectives: Therapeutic hypothermia (TH) is now standard treatment for moderate to severe hypoxic ischemic encephalopathy (HIE), secondary to intrapartum hypoxia, and has been performed in ...
Publikováno v:
Methods in Ecology and Evolution. 9:245-253
Context Methods to quickly measure organic matter degradation have been well developed for terrestrial and freshwater ecosystems. However, these methods have not been adapted to marine environments. Current methods of assessing organic matter degrada
Autor:
Emma Gibbs, George Hruby, Matthew Wong, Stephen Clarke, Connie I. Diakos, Malinda Itchins, Sia Kim, Terence C. Chua, J. Rabindran, Anubhav Mittal, Richard Maher, Jennifer Arena, Christopher B. Nahm, Jaswinder S. Samra, Anthony J. Gill, Nick Pavlakis, Sarah Bergamin, Andrew Kneebone
Publikováno v:
European Journal of Surgical Oncology. 43:1711-1717
Background Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease. Neoadjuvant therapy (NA) with chemotherapy (NAC) and radiotherapy (RT) prior to surgery provides promise. In the absence of prospective data, well annotated clinical data from hi
Autor:
Felix Hilpert, Madeleine King, Martin R. Stockler, Lucy Claire Davies, Val Gebski, Felicia Roncolato, Michael Friedlander, Eric Pujade-Lauraine, Rebecca Asher, Chee Khoon Lee, Emma Gibbs, Lari Wenzel
Publikováno v:
Annals of Oncology. 28:1849-1855
BACKGROUND: Women with platinum-resistant ovarian cancer are a heterogeneous group whose median overall survival is 12 months. We hypothesized that their quality of life (QoL) scores would be prognostic. PATIENTS AND METHODS: Data from AURELIA (n = 3
Publikováno v:
The AustralianNew Zealand journal of obstetricsgynaecologyReferences. 60(3)
Background Expediting delivery in the second stage of labour often involves a choice between a caesarean section at full dilatation or mid-cavity instrumental delivery. Accumulating evidence suggests that the mode of delivery may influence the risk o